Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients
- 27 September 2023
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (11) , 1621-1637
Abstract
Background and Objective Escitalopram and sertraline are commonly prescribed for anxiety and depressive disorders in children and adolescents. The pharmacokinetics (PK) of these medications have been evaluated in adults and demonstrate extensive variability, but studies in pediatric patients are limited. Therefore, we performed a population PK analysis for escitalopram and sertraline in children and adolescents to characterize the effects of demographic, clinical, and pharmacogenetic factors on drug exposure. Methods A PK dataset was generated by extracting data from the electronic health record and opportunistic sampling of escitalopram- and sertraline-treated psychiatrically hospitalized pediatric patients aged 5–18 years. A population PK analysis of escitalopram and sertraline was performed using NONMEM. Concentration-time profiles were simulated using MwPharm++ to evaluate how covariates included in the final models influence medication exposure and compared to adult therapeutic reference ranges. Results The final escitalopram cohort consisted of 315 samples from 288 patients, and the sertraline cohort consisted of 265 samples from 255 patients. A one-compartment model with a proportional residual error model best described the data for both medications. For escitalopram, CYP2C19 phenotype and concomitant CYP2C19 inhibitors affected apparent clearance (CL/F), and normalizing CL/F and apparent volume of distribution (V/F) to body surface area (BSA) improved estimations. The final escitalopram model estimated CL/F and V/F at 14.2 L/h/1.73 m2 and 428 L/1.73 m2, respectively. For sertraline, CYP2C19 phenotype and concomitant CYP2C19 inhibitors influenced CL/F, and empirical allometric scaling of patient body weight on CL/F and V/F was significant. The final sertraline model estimated CL/F and V/F at 124 L/h/70 kg and 4320 L/70 kg, respectively. Normalized trough concentrations (Ctrough) for CYP2C19 poor metabolizers taking escitalopram were 3.98-fold higher compared to normal metabolizers (151.1 ng/mL vs 38.0 ng/mL, p < 0.0001), and normalized Ctrough for CYP2C19 poor metabolizers taking sertraline were 3.23-fold higher compared to normal, rapid, and ultrarapid metabolizers combined (121.7 ng/mL vs 37.68 ng/mL, p < 0.0001). Escitalopram- and sertraline-treated poor metabolizers may benefit from a dose reduction of 50–75% and 25–50%, respectively, to normalize exposure to other phenotypes. Conclusion To our knowledge, this is the largest population PK analysis of escitalopram and sertraline in pediatric patients. Significant PK variability for both medications was observed and was largely explained by CYP2C19 phenotype. Slower CYP2C19 metabolizers taking escitalopram or sertraline may benefit from dose reductions given increased exposure.Keywords
Funding Information
- National Institute of Mental Health (F31MH132265)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD069054, R01HD099775)
- National Institute of General Medical Sciences (R35GM145383)
- Cincinnati Children's Hospital Medical Center
This publication has 76 references indexed in Scilit:
- Antidepressant Exposure as a Predictor of Clinical Outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) StudyJournal of Clinical Psychopharmacology, 2011
- Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram ExposureThe Journal of Clinical Pharmacology, 2010
- In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3Drug Metabolism and Disposition, 2010
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of EscitalopramThe Journal of Clinical Pharmacology, 2009
- Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood AnxietyNew England Journal of Medicine, 2008
- The Clinical Pharmacokinetics of EscitalopramClinical Pharmacokinetics, 2007
- The Effect of Aging on the Relationship between the Cytochrome P450 2C19 Genotype and Omeprazole PharmacokineticsClinical Pharmacokinetics, 2005
- Clinical Pharmacokinetics of SertralineClinical Pharmacokinetics, 2002